US Merger & Acquisition SEC Filings — October 30, 2026

30-10-2026

BioXcel Therapeutics, Inc. and affiliates (OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC) received a final bankruptcy court order (Case No. 26-11360, D. Del.) authorizing the sale of substantially all of their assets to Teva Pharmaceuticals International GmbH as the Successful Bidder under a Stalking Horse APA dated August 27, 2026. The sale follows an extensive marketing process and a cancelled auction, with the court finding the Teva bid was the highest or otherwise best offer and that the sale maximizes estate value. No purchase price or financial consideration was disclosed in the filing, and the transaction is a Chapter 11 liquidation sale rather than a going-concern merger.

• · Bankruptcy Case No. 26-11360 (TMH), jointly administered in the U.S. Bankruptcy Court for the District of Delaware
• · Stalking Horse APA dated August 27, 2026 between the Debtors and Teva Pharmaceuticals International GmbH
• · Bidding Procedures Order entered September 28, 2026 [Docket No. 179]; auction was cancelled and Teva designated Successful Bidder
• · Sale approved free and clear of liens, claims, interests, and encumbrances under Bankruptcy Code sections 105(a), 363, and 365
• · Buyer granted good-faith purchaser protections under section 363(m); no insider relationship with the Debtors
• · Debtors' address: 555 Long Wharf Drive, 12th Floor, New Haven, Connecticut 06511
• · No purchase price or sale consideration disclosed in the order

30-10-2026

K&F Growth Acquisition Corp. II filed a proxy supplement on October 28, 2026, shortening the proposed SPAC extension period for its Extraordinary General Meeting (November 3, 2026) from a February 7, 2028 end date to August 6, 2027 — a reduction of roughly 18 months. The revised Proposal One seeks a special resolution to extend the Business Combination completion window from November 6, 2026 to August 6, 2027 (30 months after IPO closing). Proposals Two (auditor ratification of WithumSmith+Brown, PC for FY2026) and Three (adjournment) are unchanged; the filing contains no financial results or deal terms, and the shortened runway signals the SPAC has not yet secured a target combination.

• · Extraordinary General Meeting in lieu of Annual General Meeting scheduled for 11:00 a.m. Eastern Time on Tuesday, November 3, 2026, at Ellenoff Grossman & Schole LLP, 1345 Avenue of the Americas, 11th Floor, New York, NY 10105
• · Original extension sought was from November 6, 2026 to February 7, 2028; revised extension is from November 6, 2026 to August 6, 2027
• · Revised Completion Window defined as 30 months after IPO closing date (6 August 2027)
• · Proxy Statement originally dated October 6, 2026, amended October 8, 2026, and supplemented October 28, 2026
• · Votes must be submitted before 11:59 pm ET on November 2, 2026 to change or revoke prior votes
• · Shareholders may reverse redemption requests by contacting Continental Stock Transfer & Trust Company at [email protected]
• · Company's Annual Report on Form 10-K for fiscal year ended December 31, 2025 was filed March 27, 2026
• · Board recommends a vote FOR Proposals 1, 2 and 3 (if presented)
• · Company address: 1219 Morningside Drive, Suite 110, Manhattan Beach, CA 90266

30-10-2026

Copley Acquisition Corp adjourned its Extraordinary General Meeting from October 29, 2026 to November 2, 2026 to give shareholders who voted against the Extension Amendment and Trust Agreement Amendment time to reverse their votes. The Sponsor revised its monthly trust contribution upward from $150,000 to $200,000 per one-month extension through November 2, 2027, while the Company agreed to waive up to $100,000 of trust interest for dissolution expenses and all future tax-expense withdrawals from trust interest. The filing signals difficulty securing shareholder approval for the extension, with the sweetened economics and vote-reversal solicitation offset by reduced flexibility on trust funds.

• · Extraordinary General Meeting readjourns November 2, 2026 at 11:00 a.m. Eastern time, in person at Winston Taylor LLP, 800 Capitol St., Suite 2400, Houston, Texas 77002, and virtually via webcast
• · Record date for the meeting is October 19, 2026
• · Extension Amendment Proposal would allow up to 12 one-month extensions from November 2, 2026 to November 2, 2027
• · Definitive proxy statement dated October 19, 2026 and filed with the SEC on October 20, 2026
• · Revised Contribution Amount to be deposited in trust account two days prior to each applicable one-month extension
• · Company waived right to withdraw interest from trust account to pay future tax expenses (Tax Expense Waiver)
• · Trust funds held in interest-bearing demand deposit account at a bank until business combination or liquidation
• · Proxy solicitation agent: Laurel Hill Advisory Group, LLC, (855) 414-2266 / (516) 933-3100, [email protected]
• · Company is an emerging growth company; incorporated in Cayman Islands; principal offices in Central, Hong Kong
• · Exhibit 99.1 is revised Annex A to the Proxy Statement

30-10-2026

Zoned Properties closed the sale of substantially all of its assets to BPB Partners, LLC (owned by CEO/Chairman/CFO Bryan McLaren, President/COO Berekk Blackwell, and Patrick Moroney) on October 30, 2026, under an Amended and Restated Asset Purchase Agreement dated September 30, 2026, a related-party transaction that effectively liquidates the operating business. Pro forma for the Chino Property sale (closed September 2, 2026, ~$7.1M cash) and the Asset Sale, total assets fall from $13,476,364 to $11,112,086 and total liabilities plunge from $10,045,716 to $321,915, while pro forma six-month 2026 revenue drops to $0 from $1,946,413 and net income swings to a loss of $996,935 from $19,127. However, pro forma stockholders' equity rises to $10,790,171 from $3,430,648, largely reflecting gains on disposal and debt assumed by the buyer (~$7,941,163).

• · Buyer BPB Partners, LLC is owned by the Company's own Chairman/CEO/CFO Bryan McLaren, President/COO Berekk Blackwell, and Patrick Moroney — a related-party sale of substantially all assets.
• · Asset Sale closed October 30, 2026; Original APA signed January 15, 2026 and amended/restated September 30, 2026.
• · Company retained 100% interest in ZP RE AZ Dunlap, LLC, which has an active purchase and sale agreement with escrow in place.
• · 50% interest in Zoneomics Green, LLC removed from A&R APA because the entity was dissolved.
• · Pleasant Ridge Assets sale closed May 1, 2026; Green Valley and Kingman properties closed June 30, 2026; Chino Property closed September 2, 2026.
• · Pro forma six-month 2026 operating loss of $993,913 versus historical operating income of $80,332.
• · Pro forma basic loss per share $(0.08) and diluted $(0.07) versus historical $0.00.
• · Pro forma depreciation and amortization falls to $1,395 from $148,462; real estate taxes to $0 from $70,493.
• · Pro forma escrow deposits of $994,051 and cash of $9,552,671 remain after adjustments.
• · Pro forma adjustments include accumulated deficit improvement of $7,359,523 (from $18,474,810 to $11,115,287).

30-10-2026

Constellation Acquisition Corp I drew $5,000 under its unsecured promissory note with Constellation Sponsor LP and deposited the funds into its trust account, extending its deadline to complete an initial business combination from October 29, 2026 to November 29, 2026. This is the ninth of eleven permitted one-month extensions, signaling the SPAC still has not closed a deal. The note bears no interest, matures upon closing of a business combination, and would be repaid only from funds outside the trust account if no deal is consummated.

• · Extension approved by unanimous resolution of the extension committee of the board of directors dated October 29, 2026
• · Note does not bear interest and matures upon closing of the initial business combination
• · If no business combination is consummated, the Note is repayable only from amounts remaining outside the trust account, if any
• · Company is incorporated in the Cayman Islands and is an emerging growth company
• · Securities trade on OTCID Basic Market under symbols CSTAF, CSTWF, and CSTUF

30-10-2026

Edible Garden AG completed its acquisition of the Prairie Hills ready-to-drink manufacturing facility property in Webster City, Hamilton County, Iowa from Iowa Shrimp Holdings, LLC on October 30, 2026, for an aggregate purchase price of $6,325,000. The consideration was entirely non-cash: 2,500 total shares of Series B Preferred Stock valued at $2,500,000 (1,500 issued September 30, 2026 plus 1,000 issued at closing) and a $3,825,000 secured promissory note to Streeterville Capital bearing 8% interest compounded daily and maturing in five years. The deal adds a new production facility but layers on debt and preferred equity rather than cash, with the note secured by a mortgage on the acquired property.

• · The note matures five years after issuance and is secured by a real estate mortgage on the Property granted by Prairie Hills in favor of Streeterville
• · The 1,000 closing preferred shares were issued in a private transaction under Section 4(a)(2) of the Securities Act, with no underwriting discounts or commissions
• · The Property was conveyed to Edible Garden Prairie Hills LLC, a Delaware wholly owned subsidiary of the Company
• · The Purchase Contract was originally entered into on September 30, 2026
• · The Company is an emerging growth company

30-10-2026

Silicon Valley Acquisition Corp. (SVAQ), a Cayman Islands SPAC, filed an 8-K disclosing an investor day held October 27, 2026 by merger target EigenQ, Inc., a Delaware quantum-security software company. The parties entered a Business Combination Agreement on June 17, 2026 (amended four times through September 26, 2026) under which SVAQ will domesticate to Delaware and merge Merger Sub into EigenQ, making EigenQ a wholly-owned subsidiary. The filing furnishes an investor presentation (Exhibit 99.1) and transcript (Exhibit 99.2) but contains no financial figures, deal valuation, or redemption data, and the transaction remains subject to shareholder approval and closing conditions.

• · Business Combination Agreement originally dated June 17, 2026; amended August 6, 2026, September 17, 2026, and September 26, 2026
• · SVAQ will transfer by way of continuation from the Cayman Islands to Delaware (Domestication) prior to closing
• · Merger Sub will merge into EigenQ, with EigenQ surviving as a wholly-owned subsidiary of SVAQ
• · Investor Day held October 27, 2026; presentation furnished as Exhibit 99.1 and transcript as Exhibit 99.2
• · SVAQ's 2025 Annual Report on Form 10-K was filed March 31, 2026
• · Transaction requires SVAQ shareholder approval at an extraordinary general meeting; definitive proxy statement not yet effective
• · SVAQ is an emerging growth company; SEC file number 001-43030; EIN listed as N/A
• · Forward-looking statements cite risks including shareholder redemptions, regulatory approval, and quantum-security government mandates

30-10-2026

Leader's Advantage Acquisition Corp., a healthcare-focused blank check company, closed the partial exercise of its underwriters' over-allotment option on October 29, 2026, selling an additional 650,000 units at $10.00 per unit for gross proceeds of approximately $6,500,000. This raised total units sold in the IPO to 15,650,000 and total gross proceeds to $156,500,000 before underwriting discounts and offering expenses. The filing is a routine post-IPO capital-raising update, not an actual business combination; the company has yet to identify or complete a target transaction.

• · Units began trading on the Nasdaq Global Market on September 18, 2026 under ticker LEDRU.
• · Registration statement declared effective by the SEC on September 17, 2026.
• · Each unit consists of one Class A ordinary share and one-half of one redeemable warrant; no fractional warrants will be issued.
• · Upon separation, Class A shares and warrants are expected to trade under LEDR and LEDRW, respectively.
• · Clear Street LLC acted as lead book-running manager; D. Boral Capital LLC acted as bookrunner.
• · Company is a blank check company (SIC 6770) incorporated in the Cayman Islands, EIN 98-1898982, SEC File No. 001-43442.
• · Target strategy focuses on healthcare businesses with first-in-class drug candidates in large addressable markets.
• · No business combination target has been identified or completed; proceeds are held pending a future transaction.